Dermatomycoses market set for growth with new antifungal drugs and AI diagnostics through 2035

The global dermatomycoses market is expected to grow significantly through 2035, driven by rising fungal infections, increased hygiene awareness, and a growing immunocompromised population. Advances in antifungal treatments, including nanopharmaceuticals and combination therapies, alongside innovations in diagnostic tools like digital PCR and AI, are improving treatment efficacy and access. Challenges such as antifungal resistance and systemic drug side effects remain, but ongoing research and technology integration promise to sustain market expansion. Major pharmaceutical players are investing in R&D and digital platforms to capitalize on these trends and meet rising demand worldwide.